MiRmap: Comprehensive Prediction of MicroRNA Target Repression Strength
Overview
Authors
Affiliations
MicroRNAs, or miRNAs, post-transcriptionally repress the expression of protein-coding genes. The human genome encodes over 1000 miRNA genes that collectively target the majority of messenger RNAs (mRNAs). Base pairing of the so-called miRNA 'seed' region with mRNAs identifies many thousands of putative targets. Evaluating the strength of the resulting mRNA repression remains challenging, but is essential for a biologically informative ranking of potential miRNA targets. To address these challenges, predictors may use thermodynamic, evolutionary, probabilistic or sequence-based features. We developed an open-source software library, miRmap, which for the first time comprehensively covers all four approaches using 11 predictor features, 3 of which are novel. This allowed us to examine feature correlations and to compare their predictive power in an unbiased way using high-throughput experimental data from immunopurification, transcriptomics, proteomics and polysome fractionation experiments. Overall, target site accessibility appears to be the most predictive feature. Our novel feature based on PhyloP, which evaluates the significance of negative selection, is the best performing predictor in the evolutionary category. We combined all the features into an integrated model that almost doubles the predictive power of TargetScan. miRmap is freely available from http://cegg.unige.ch/mirmap.
Investigation of the role of miRNA variants in neurodegenerative brain diseases.
Frydas A, Cacace R, van der Zee J, Van Broeckhoven C, Wauters E Front Genet. 2025; 16:1506169.
PMID: 40078479 PMC: 11897046. DOI: 10.3389/fgene.2025.1506169.
miRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma.
Piccioni M, Di Meo F, Valentino A, Campani V, Arigoni M, Tanori M J Exp Clin Cancer Res. 2025; 44(1):65.
PMID: 39984959 PMC: 11846362. DOI: 10.1186/s13046-025-03283-0.
A Practical Guideline for MicroRNA Sequencing Data Analysis in Chronic Lymphocytic Leukemia.
Suomela T, Zhang L, Vera J, Bruns H, Lai X Methods Mol Biol. 2024; 2883:403-426.
PMID: 39702719 DOI: 10.1007/978-1-0716-4290-0_18.
Gholami M, Asouri M, Ahmadi A Health Sci Rep. 2024; 7(12):e70228.
PMID: 39640032 PMC: 11618408. DOI: 10.1002/hsr2.70228.
Identification of SLC31A1 as a prognostic biomarker and a target for therapeutics in breast cancer.
Fu H, Dong S, Li K Sci Rep. 2024; 14(1):25120.
PMID: 39448672 PMC: 11502855. DOI: 10.1038/s41598-024-76162-x.